/CRBP
CRBP Stock - Corbus Pharmaceuticals Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$8.12+0.25%
+$0.02 (+0.25%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.26
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.11
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+433.6%upside
Target: $43.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRBP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.04 – $8.20
TARGET (TP)$43.33
STOP LOSS$7.47
RISK/REWARD1:54.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.72
52W High$20.56
52W Low$4.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $881,705 | $3.94M |
| Gross Profit | $-600,000 | N/A | $-1,487,853 | $-757,527 | $3.94M |
| Gross Margin | N/A | N/A | N/A | -85.9% | 100.0% |
| Operating Income | $-48,721,000 | $-45,078,000 | $-34,835,445 | $-55,989,024 | $-122,810,233 |
| Net Income | $-40,209,000 | $-44,604,000 | $-55,833,193 | $-45,552,588 | $-111,269,380 |
| Net Margin | N/A | N/A | N/A | -5166.4% | -2826.1% |
| EPS | $-3.68 | $-10.31 | $-10.15 | $-11.11 | $-42.74 |
Company Overview
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$69
Average Target
↑ 746.2% Upside
Now
$28
Low
$69
Average
$85
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 30th 2025 | B. Riley Securities | Resumed | Buy | $28 |
| February 28th 2025 | William Blair | Initiation | Outperform | - |
| December 2nd 2024 | Piper Sandler | Initiation | Overweight | - |
| July 30th 2024 | Wedbush | Initiation | Outperform | $85 |
| July 22nd 2024 | H.C. Wainwright | Resumed | Buy | $80 |
| June 26th 2024 | B. Riley Securities | Initiation | Buy | $85 |
| June 3rd 2024 | Oppenheimer | Reiterated | Outperform | $80← $60 |
| May 13th 2024 | RBC Capital Mkts | Initiation | Outperform | $77 |
| March 6th 2024 | Jefferies | Upgrade | Buy | $46← $4 |
Earnings History & Surprises
CRBPBeat Rate
50%
Last 18 quarters
Avg Surprise
+7.1%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-1.90
Q4 2025
EPS Surprise History
Q1 24
+23.3%
$-1.81vs$-2.36
Q2 24
+23.9%
$-0.83vs$-1.09
Q3 24
+22.4%
$-0.90vs$-1.16
Q4 24
-16.2%
$-1.15vs$-0.99
Q1 25
+23.5%
$-0.78vs$-1.02
Q2 25
-10.3%
$-1.39vs$-1.26
Q3 25
+7.1%
$-1.44vs$-1.55
Q4 25
-5.6%
$-1.90vs$-1.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-1.78 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.80 | $-1.90 | -5.6% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-1.55 | $-1.44 | +7.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.26 | $-1.39 | -10.3% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-1.02 | $-0.78 | +23.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.99 | $-1.15 | -16.2% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-1.16 | $-0.90 | +22.4% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.09 | $-0.83 | +23.9% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-2.36 | $-1.81 | +23.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-2.06 | $-2.27 | -10.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-3.10 | $-2.05 | +33.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-4.09 | $-4.24 | -3.7% | ✗ MISS |
Q1 2023 | Mar 7, 2023 | $-2.10 | $-2.61 | -24.3% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-1.80 | $-2.10 | -16.7% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-1.80 | $-2.10 | -16.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-2.70 | $-2.40 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-3.30 | $-2.40 | +27.3% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-3.60 | $-0.60 | +83.3% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-3.60 | $-4.50 | -25.0% | ✗ MISS |
Latest News
Corbus Pharmaceuticals Highlights Safe, Well-Tolerated CRB-913 Phase 1a Results With Emerging Evidence Of Weight Loss In Obesity
📈 PositiveBenzinga•Dec 11, 2025, 12:08 PM
Corbus Pharmaceuticals To Release Phase 1a Results For Obesity Drug CRB-913 On December 11, 2025
➖ NeutralBenzinga•Dec 10, 2025, 09:01 PM
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $53
📈 PositiveBenzinga•Nov 13, 2025, 05:33 PM
Corbus Pharmaceuticals Q3 EPS $(1.90) Misses $(1.72) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 01:08 PM
Corbus Pharmaceuticals Holdings shares are trading lower after the company announced the pricing of its $75 million public offering.
📉 NegativeBenzinga•Oct 31, 2025, 02:52 PM
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share
📉 NegativeSeeking Alpha•Oct 31, 2025, 10:10 AM
Corbus Pharmaceuticals Prices $75M Public Offering Of 4,744,231 Common Stock And Pre-Funded Warrants At $13.00 Per Share To Advance Oncology And Obesity Pipeline
➖ NeutralBenzinga•Oct 31, 2025, 07:10 AM
Corbus Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Oct 30, 2025, 08:49 PM
Corbus Pharmaceuticals announces proposed public offering to fund clinical pipeline
➖ NeutralSeeking Alpha•Oct 30, 2025, 08:41 PM
Corbus Pharmaceuticals Announces Proposed Public Offering, Size Not Given
➖ NeutralBenzinga•Oct 30, 2025, 08:37 PM
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $38
📈 PositiveBenzinga•Oct 20, 2025, 01:16 PM
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:44 AM
Reported Saturday, Corbus Pharmaceuticals Presents CRB-701 Data At European Society For Medical Oncology 2025 Showing 47.6% Objective Response Rate In Head And Neck Squamous Cell Carcinoma, 37.5% In Cervical Cancer, And 55.6% In Urothelial Tumors
📈 PositiveBenzinga•Oct 20, 2025, 08:25 AM
Corbus Pharmaceuticals Releases Abstract For Its Phase 1/2 Oncology Study Ahead Of Presentation At ESMO Congress 2025. Abstract Includes Safety Data From 70 Participants
📈 PositiveBenzinga•Oct 14, 2025, 12:07 PM
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Sep 17, 2025, 10:26 AM
Corbus higher as FDA issues another fast track tag for lead asset
📈 PositiveSeeking Alpha•Sep 16, 2025, 02:34 PM
FDA Grants Fast Track Designation To Corbus Pharmaceuticals' Nectin-4 For Head And Neck Squamous Cell Carcinoma
📈 PositiveBenzinga•Sep 16, 2025, 12:01 PM
Frequently Asked Questions about CRBP
What is CRBP's current stock price?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is currently trading at $8.12 per share. The stock has moved +0.25% today.
What is the analyst price target for CRBP?
The average analyst price target for CRBP is $43.33, based on 1 analyst.
What sector is Corbus Pharmaceuticals Holdings, Inc. in?
Corbus Pharmaceuticals Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRBP's market cap?
Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does CRBP pay dividends?
No, Corbus Pharmaceuticals Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$29.69
Mkt Cap: $0.4B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
Explore stocks similar to CRBP for comparison